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High levels of drug dependence have been observed in the prison population globally, and the sharing of injecting drug equipment in 
prisons has contributed to higher prevalence of bloodborne diseases in prisoners than in the general population. WHO, UNODC, and UNAIDS 
have advised governments to instituteFew prison needle and syringe programs (PNSPs), but few such programs) exist. We conducted a 
systematic review to assess evidence regarding health outcomes of PNSPs. We searched peer-reviewed databases (Medline, Embase, 
PsycINFO, and CINAHL) for data relating to needle and syringe programs in prisons. The search methodology was conducted in accordance 
with PRISMA MOOSEaccepted guidelines. Five studies met review inclusion criteria, and all presented evidence associating PNSPs with one 
or more health benefits, but the strength of the evidence was low. The outcomes for which the studies collectively demonstrated the strongest 
evidence were prevention of HIVhuman immunodeficiency virus and viral hepatitis. Few negative consequences from PNSPs were observed, 
consistent with previous evidence assessments. More research is needed on PNSP effectiveness, and innovative study designs are needed to 
overcome methodological limitations of previous research. Until stronger evidence becomes available, policy-makerspolicymakers are urged to 
recognize that not implementing PNSPs has the potential to cause considerable harm, in light of what is currently known about the risks and 
benefits of NSPsneedle and syringe programs and PNSPs and about the high prevalence of HIV, HBV and HCVhuman immunodeficiency virus 
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INTRODUCTION 
There are ten10 million people in prisons worldwide, and high levels of drug dependence have been observed in prison populations (1, 2). Some 
people who injected drugs before they were incarcerated continue to do so while in prison, whilewhereas other people initiate injecting drug use 
in prison (2–4). In studies in Australia, England, the Netherlands, and Thailand, the proportions of inmates who reported injecting drugs while in 
prison were 52%, 12%, 3%%, and 25%, respectively (2). 
Health consequences of injecting drug use include exposure to bloodborne viruses as a result of sharing contaminated injecting equipment, and 
prison inmates often have higher prevalence of bloodborne diseases than does the general population. AAccording to a 2016 meta-analysis 
determined that, worldwide prevalence of human immunodeficiency virus (HIV) among prison inmates is 3.8%, whileand 4.8% of inmates are 














(HCV),) antibodies, meaning that they have been exposed to HCV but do not necessarily have chronic infection (4). AnotherOn the basis of 
findings of another meta-analysis focusing, which focused specifically on HCV in prisons reported an, researchers estimated more than one-
quarter of inmates worldwide to beare HCV antibody- positive (5). 
There is less evidence regarding the extent to which people are becoming infected with HIV, HBV, and HCV during periods of incarceration as 
opposed to acquiring these viruses before entering prison. Furthermore, injecting drug use is only one1 of multiple transmission pathways that 
are commonly found in prisons, and; other practices, such as sharing contaminated tattooing equipment, also contribute to the spread of 
bloodborne viruses among inmates. However, the scarcity of injecting drug equipment in prisons leads to the available equipment being widely 
shared, and major outbreaks of HIV in several countries have been linked to injecting drug use among inmates (2, 6, 7). ResearchResearchers 
also hashave documented new HCV infections attributable to injecting drug use among inmates (8). 
TheIn 1983, the Amsterdam Health Department initiated the world’s first-ever government-run needle and syringe program (NSP) for people 
who inject drugs (PWID) in 1983.). Although preventing HBV transmission among PWID was the immediate concern, health officials soon 
recognized the NSP as a strategy for responding to the emerging HIV epidemic (9). FollowingAfter the documented success of the Amsterdam 
NSP, similar programs were implemented in Australia, the United Kingdom, and the United States (10). 
A number ofSeveral systematic reviews of NSP research have been published. In a 2017 overview of systematic reviews, Fernandes et al. (11) 














evidence drawn solely from prison populations, in light of their assessment that prison and non-prisonnonprison populations have distinct 
characteristics. Their studyThey found some review-level evidence that NSPs reduce HIV transmission among PWID. Findings were mixed 
regarding whether NSPs reduce HCV transmission. The researchers concluded that evidence relating to the impacteffect of NSPs is highly 
heterogeneous and of low methodological quality overall (11). Davis et al. (12) made a similar observation in a systematic review and meta-
analysis focusing specifically on HCV risk. Among the six6 studies that met their review criteria, pooled hazard ratios from four4 studies 
indicated that NSPs had a statisticially significant harmful effect, in terms of the association between NSP use and HCV seroconversion, 
whilewhereas pooled risk ratios from two2 studies indicated that NSP participation had no effect. The authors concluded that the existing 
empirical evidence iswas not sufficient to either recommend or discount NSPs as an HCV prevention strategy (12). In a Cochrane systematic 
review that only included studies comparing multiple study arms, seven7 studies collectively provided weak evidence associating high NSP 
coverage with a lower risk of HCV acquisition (13). 
Nonetheless, in lighton the basis of what is known about the potential benefits of NSPs, the World Health Organization (WHO) and other major 
public -health stakeholders have strongly endorsed this intervention, as have harm reduction service providers and members of communities 
affected by injecting drug use (14–16). As of 2016, 90 countries were reported to have at least one1 operational needle and syringe programNSP 
(17). At the same time, concerns have been raised about whether the existing evidence is strong enough to justify the intervention. Designing and 














with challenges – —from losing study participants to follow-up to the limited generalizability of findings due to non-probablisticnonprobablistic 
sampling methodologies. 
The international community has recognized the principle of equivalence in relation to the treatment of prisoners, meaning that governments 
have the obligation to provide prisoners with the same level of care that is available to the non-prisonnonprison population. In 1990, the United 
Nations General Assembly adopted a resolution that committed Member States to providing prisoners with “access to the health services 
available in the country without discrimination on the grounds of their legal situation” (18, p. 1). In 1993, in a recommendation addressing HIV 
in prisons, the Council of Europe similarly pronounced that “respect for the fundamental rights of prisoners, in particular the right to health care, 
entails the provision to prisoners of preventive treatment and health care equivalent to those provided to the community in general” (19, p. 1). 
WHO, the United Nations Office on Drugs and Crime (UNODC), and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have 
further elaborated on governments’ responsibilities in relation to the provision of equivalent health care to prisoners, as has the World Medical 
Association (20, 21). 
AIn 1992, a prison physician in Switzerland initiated the first known prison-based NSP (PNSP) in 1992 (22, 23). The prison director’s support 
for this activity proved to be atypical, and few other prisons followed suit (24). Harm Reduction International reported that only eight8 countries 
worldwide were providing NSPs in at least one1 prison in 2016: Armenia, Germany, Kyrgyzstan, Luxembourg, Moldova, Spain, Switzerland, 














InBy not implementing PNSPs more widely, governments are disregarding the advice of WHO, which first publicly supported PNSPs in 1993 
(27). A landmark technical paper co-publishedcopublished in 2007 by WHO, UNAIDSJoint United Nations Programme on HIV/AIDS, and 
UNODCUnited Nations Office on Drugs and Crime presented a thorough assessment of the available evidence on PNSPs. The body of evidence 
as a whole had major methodological limitations, including extensive reliance on descriptive findings from evaluation studies. Generally, 
however, it supported the premise that PNSPs reduce the sharing of non-sterilenonsterile injecting equipment. The dearth of evidence for serious, 
unintended, negative consequences of PNSPs was noted as well. According to WHO, opposing the implementation of PNSPs on the grounds of 
incomplete scientific evidence would be considered “both poor scientific judgment and bad public health policy” (8, p. 18, 28). While 
acknowledgingAlthough they acknowledged that more evidence was needed, WHO and the other agencies concluded that on the basis of what 
was then known, “Prison“[p]rison authorities in countries experiencing or threatened by an epidemic of HIV infections among (injecting drug 
users) should introduce needle and syringe programs urgently and expand implementation to scale as soon as possible” (8, p. 18). In making the 
case for PNSPs, they cited the more widely available evidence of the benefits of non-prisonnonprison NSPs (8). 
WHO reiterated the PNSP recommendation in 2014, basing its position on an updated literature review. The 2014 publication, like the 2007 one, 
noted additional possible benefits of PNSPs beyond reducing HIV transmission. These included reducing the risk of drug overdose and 















There has been a sustained global movement to end the HIV epidemic for more than two decades20 years (29, 30). More recently, growing 
recognition of the burden of disease from HBV and HCV has led to the emergence of globally coordinated responses to both diseases, and, in 
2016, WHO introduced the goal of eliminating viral hepatitis “as a major public health threat” by 2030 (31, p. 21). Injecting drug use is a major 
driver of the transmission of all three3 diseases in prison populations. However, there do not appear to be any systematic reviews of evidence 
relating to health outcomes of prison-based NSPs. ThisIn this article seeks, we seek to fill an important gap in the literature by presenting the first 
such study. 
METHODS 
A search was conducted in the following four4 bibliographic databases to identify studies of needle and syringe programsNSPs in prisons: 
MEDLINE (via Ovid), Embase (via Ovid), PsycINFO, (via Ovid) and Cumulative Index to Nursing and Allied Health Literature (CINAHL (; via 
EBSCOhost). Each was searched from inception to January 26, 2017. Searches were conducted by combining terms related to prisons or 
prisoners (e.g., prisons, jail, penitentiary, correctional facility, custody, detainee and, incarcerated) and needle and syringe programsNSPs (e.g., 
needles, syringes, exchange, provision, distribution, and program). 
The appropriate indexing terms and free -text searches were applied for each database (Web Appendix 1, available at 
https://academic.oup.com/aje). Results were limited to include only records indexed as involving humans. No language or geographic restrictions 














ofremoving duplicates, the titles and abstracts of the remaining records were manually screened to identify potentially relevant studies and to 
establish types of potential health outcomes. Google Scholar was used to check if the search string had missed any relevant studies. 
A study was considered for inclusion if it focused on a prison needle and syringe program,PSNP, if the authors had outlined how it was 
conducted, and reportedif any health outcomes observed as a result of the intervention. were reported. Studies that did not aim to measure health 
outcomes among PWID in prisons, but reported them as unintended benefits, were also considered for inclusion. Health outcomes were defined 
as any change in the health status of study participants, including behavioral changes (e.g., reduced risk behavior) and infection rate changes in 
HIV and/or viral hepatitis. Health outcomes could have been measurable or they could have been self-perceived and self-reported by PNSP 
clients and/or providers. Studies reporting quantitative and/or qualitative findings on any health-related outcome of these programs were eligible 
for inclusion. Studies reporting results of PNSP as part of a package of interventions (e.g., harm reduction services) were considered for inclusion 
if a PNSP-specific subanalysis was conducted. All types of PNSP interventions were considered for inclusion, regardless of the type of needle 
and syringe distribution mode (e.g., hand-to-hand, vending machine). Original research articles and review articles, systematic or otherwise, were 
eligible for inclusion. Studies based on surveys, interviews, case studies, ethnographic research, and intervention research were all eligible for 
inclusion. Articles published as comments, editorials, letters, or narrative reviews were excluded, as were studies that addressed the 














A data extraction template was utilizedused and included bibliographic details, study design, intervention, and measureable health outcomes 
among clients of PNSPs. Two members of the study team reviewed the articles, extracted the data, and compared the findings. 
All components of the search methodology were conducted in accordance with PRISMA MOOSEPreferred Reporting Items for Systematic 
Reviews and Meta-Analyses and Meta-analysis of Observational Studies in Epidemiology guidelines for systematic reviews (32). Study quality 
was assessed by members of the study team, and limitations to the designs of included studies were noted. Due to the overall lack of studies 
included in the review, inconsistent study designs, different levels of measurements, and substantial variation between study settings, a statistical 
test for heterogeneity was not conducted. 
RESULTS 
The search yielded 745 records, of which 378 were eliminated because they were duplicates. Title and abstract screening of the remaining 367 
articles resulted in the exclusion of 306 articles. All of the remaining 61 articles underwent full-text screening; five5 met the inclusion criteria 
and were included in the final review (Figure 1). No other studies were identified through an additional Google Scholar search. 
 The studies included in the final analysis were conducted in Germany (n = 3), Spain (n = 1), and Switzerland (n = 1) (Table 1). 
Ferrer-Castro et al. (33) tested prisoners in the Pereiro de Aguiar prison in Spain for HBV, HCV, and HIV in 1999, then again in 2009 after the 














prevalence dropped from 21% to 8% (P ≤ 0.01) and HCV prevalence dropped from 40% to 26% (P ≤ 0.01). There was no significant change in 
HBV antibody prevalence, which was already quite low (2%) at baseline. 
Between 1996 and 1997, Heinemann et al. (34) conducted a mixed-methods study in a German prison, with; data were gathered via survey, blood 
samples, and patient records, including drug consumption patterns (34).. The researchers found no new HIV or hepatitis infections among PWID 
after the initiation of a PNSP. There was also no change in knowledge of hepatitis and associated risks. An increase in drug consumption among 
a subset of study participants taking methadone was observed. 
In a comparative PNSP pilot study that took place in one1 all-female (n = 169) and one1 all-male (n = 83) prison in Germany, researchers 
reported no new HIV or hepatitis infections, an overall reduction in risk behavior, no overdoses at the all-female facility, and one1 overdose at 
the all-male facility (35, 36). The all-female prison observedThere was a decrease in injecting-related abscesses and a decrease in psychological 
disorders requiring treatment. There was furthermore at the all-female prison. Furthermore, there was no evidence of an increase in drug 
consumption. 
Between 1994 and 1995, researchers conducted a PNSP pilot study in an all-female prison in Switzerland (n = 137) observed no new infections 
of HIV, HBV, or HCV during the study period (37). Likewise, no increased drug use was observed and participants discontinued the sharing of 















Finally, in a PNSP study in Berlin, Germany, measured HIV, HBV, and HCV seroconversions were measured among PWID in one1 all-male and 
one1 all-female prison (n = 174, both sexes) (38). The baseline seroprevalencesseroprevalence for HIV, HBV, and HCV werewas 18%, 53%, and 
82%, respectively. No seroconversions occurred during follow-up (n = 124, both sexes), and one1 new case of HCV was recorded in the all-male 
prison. 
DISCUSSION 
This systematic review was conducted to assess the current state of evidence regarding health benefits of PNSPs, an intervention recognized as 
an important HIV and HCV prevention strategy but rarely implemented in correctional settings worldwide. While fiveAlthough 5 studies 
identified in our review presented evidence associating PNSPs with one1 or more health benefits, the overall strength of the findings was low. 
However, the studies collectively indicated that PNSPs appear to contribute to the prevention of HIV, HBV, and HCV transmission among 
prison inmates. Anecdotal evidence suggested additional benefits, including decreased risk behavior, fewer drug use-–related abscesses, 
decreased incidence of psychological disorders requiring treatment, increased uptake of other harm reduction services, improved infectious 
disease-–related knowledge among inmates, and almost no drug overdoses. There were conflicting findings regarding whether PNSPs was 
associated with reduced drug consumption among study populations. 
Paralleling the findings of two non-prison2 nonprison NSP reviews, thiswe found in the present review foundthat methodological weaknesses to 














and prison populations. It is also notable that only two2 of the studies were published more recently than 2000. Taken together, these issues make 
it difficult to draw meaningful conclusions from the studies about the general effectiveness of PNSPs. 
This situation likely reflects the inherent difficulty of conducting methodologically robust research on the provision of clean injecting equipment 
in prisons. High turnover in the prison population in many settings is an obstacle to following large numbers of individuals longitudinally,  (i.e., 
the transfer or release of study participants means that they are not available for follow-up unless there is a mechanism for tracking and retaining 
them in the study. Additionally). In addition, in some studies in our review, clean needles and syringes were provided alongsidealong with other 
interventions such as condom distribution, health education activities, and referral to drug treatment services. This is consistent with evidence-
based advice from UNODCthe United Nations Office on Drugs and Crime and other UNUnited Nations agencies to implement PNSPs as part of 
a comprehensive package of harm reduction services (39). From a scientific standpoint, the simultaneous use of multiple interventions makes it 
difficult to attribute any observed changes to onea specific intervention. From an ethical standpoint, however, it would not be acceptable to 
conduct a study that gave prison inmates access to one1 intervention but not other interventions that have been shown to have health benefits. 
Therefore, it is necessary to explore other methodological approaches for assessing the effectiveness of PNSPs. 
The question facing policy-makers – policymakers—an urgent question in many settings, in light of the high HIV, HBV, and HCV prevalence in 
prison populations – —is whether or not to institute PNSPs on the basis of the existing body of knowledge. Typically, evidence-based medical 














study situations –, before new interventions are endorsed as good practices. However, in the context of a public health crisis that health officials 
do not have the means to contain effectively, it may be justifiable to implement strategies on the basis of less-than-ideal evidence. For example, 
when the Thai government targeted all of the nation’s sex work establishments with the “100% condom use” program to combat HIV in the early 
1990s, there was little direct evidence that an intervention of that nature would reduce HIV transmission, and critics of the initiative questioned 
its feasibility. Thailand went on to experience a sharp decline in new HIV cases, and “100% condom use” became recognized as a key factor in 
enabling the country to avoid a much larger HIV epidemic (40, 41). 
The potential risks and benefits of not scaling up a promising intervention need to be considered alongside the potential risks and benefits of 
taking action. In the case of PNSPs, the provision of clean injecting equipment to PWID outside of prisons is, in fact, considerably more than a 
“promising” approach to reducing transmission of bloodborne viruses. There is widespread consensus among diverse stakeholders regarding the 
beneficial public health impact of NSPs (8). WhileAlthough it is acknowledged that some of the available evidence does not embody the highest 
empirical standards in public health research, the perceived public health gains are of sufficient magnitude to warrant allocating financial and 
human resources to the provision of this intervention in many settings, and the failure to implement a NSP cannot be justified by the current body 
of evidence or lack thereof (42). SinceBecause clean injecting equipment has the same potential to protect the health of prisoners as non-
prisonersit does for nonprisoners, it thus makes sense to provide this intervention unless one1 or more unique features of prison settings present 














Opponents of PNSPs have suggested that providing clean injecting equipment to prisoners may result in harmful drug use-–related outcomes 
(43). Not all of the studies identified in our review reported on this issue, but among those that did, researchers generally observed minimal or no 
harmful drug-–use related outcomes. The exception is a 2001 study that found that prisoners on methodone substitution treatment were at a 
higher risk of taking drugs again followingafter the initiation of a PNSP at a prison in Germany (35). It may be that some context-specific 
characteristics of prison populations and prison settings result in a different risk-benefit ratio than non-prisonnonprison settings, and it is 
important for future studies examining the impacteffect of PNSPs to continue looking for any evidence of harmful drug-–use related outcomes in 
addition to evidence of health benefits (39). 
Opponents of PNSPs also have suggested that needles might be used as weapons against other prisoners or staff, or might otherwise cause harm 
(44). OneIn 1 of the studies in our review, it was reported that neither needles nor syringes were used as weapons, while; the othersother studies 
did not address this issue. In a study that did not meet the review inclusion criteria, correctional officers who participated in an evaluation after 
22 months of implementation of a PNSP in Spain reported that prisoners had never used needles as weapons (44). AnotherIn another study that 
did not meet review inclusion criteria, researchers showed that the availability of syringes and needles meant that prisoners no longer had to hide 
them, resulting in fewer injuries when staff conducted cell searches (45). However, authors of an article in our review reported seeing no 
improvement regarding the number of needles being hidden by inmates after the start of the PNSP (35). Future studies should continue to address 
this issue asbecause strong observational evidence could be used to either to further corroborate the safety of PNSPs or to call attention to ways 














Methodologies for future PNSP studies need to take into account that HCV can survive for a long periods of time outside the human body. In 
prison settings, it is not uncommon to share multiple objects that may be contaminated with HCV, such as razors, toothbrushes, and tattooing 
equipment (46, 47). This has implications for efforts to assess whether PNSPs reduce HCV transmission levels, sincebecause transmission can 
occur through pathways unrelated to injecting drug use. Mixed-methods approaches have the potential to help researchers account for such 
factors and to document incident cases of HCV in prison settings with greater certainty about transmission pathways. 
The paucity of PNSPs worldwide raises the question of whether the stigmatized nature of injecting drug use has contributed to the lack of policy 
action (48). There does not appear to be any research addressing this issue, but the absence of PNSPs in many countries with high levels of HIV 
and HCV among prison populations is striking in light ofgiven the strong and consistent recommendations issued by UNUnited Nations technical 
experts. It is particularly notable that WHO’s first endorsement of PNSPs came in 1993 and that this agency reiterated its recommendation in 
favor of PNSPs followingafter a 2014 evidence review (1, 8). 
Efforts to overcome political resistance to PNSPs should directly address the issue of stigma and should encourage policy-makerspolicymakers 
and their constituents to consider whether there is any basis in evidence for their concerns about the negative consequences of PNSPs. A related 
issue is that endorsing PNSPs constitutes a tacit acknowledgment that illegal drugs are circulating in prisons, and government officials may fear 














substance use disorders to continue seeking drugs while in prison, may help to reframe this issue, with PNSP presented as part of a 
comprehensive package of interventions that address inmates’ health needs. 
A furtherAnother policy consideration in relationrelative to inmate health is the legal and human rights principle of equivalence. Where NSPs are 
available to PWID outside of prisons –, as is the situation in 90 countries worldwide –, the denial of the same service within prisons violates this 
principle (17). Again, there is a role for education: makingMaking people more aware of the successful functioning of NSPs in the community, 
and of their health benefits, can foster an understanding of PNSPs as a necessary aspect of providing inmates with the same health services to 
which the general population is entitled. 
It is also important for policy-makerspolicymakers to understand the public health gains that can be achieved by implementing PNSPs. The high 
prevalence of bloodborne diseases in prison populations, coupled with the frequent movement of some individuals between prison and non-
prisonnonprison settings, may facilitate the spread of these diseases, within and outside of prisons (7). Making more headway in regard to prison 
disease prevention can therefore be expected, therefore, to contribute to lowering disease incidence and prevalence in the community more 
broadly (8). 
Prison-based harm reduction programs are vulnerable to budget restrictions and financial crises. This may be a factor contributing to the absence 
of PNSPs worldwide. Decreases in contributions allocated for harm reduction services from donors such as The Global Fund have increased the 














unclear how current decreases in government and donor funding have directly affected PNSPs. However, many such programs are federally 
funded and are traditionally resource- challenged. 
Findings from this review leadled the authors to make a number ofseveral recommendations. FirstlyFirst, PNSPs should be scaled up in 
accordance with expert guidance, and should be customized appropriately to meet the needs of different prison populations, whilewhereas 
monitoring and evaluation should be incorporated into the ongoing operation of PNSPs (50). SecondlySecond, more research is needed on the 
effectiveness of PNSPs, and funders should make it a higher priority to support this work. Researchers should seek to identify innovative study 
designs that will overcome methodological limitations identified in this article. Research on PNSPs also needs to address questions relating to 
which service -delivery models are most suitable for different types of prison settings and populations, as well as and to better 
quantifyingquantify the incidence of harmful effects of PNSPs such as increased drug use or needle-inflicted injuries. ThirdlyThird, the role of 
stigma in discouraging policy action on PNSPs should be addressed through multifaceted strategies, including education framing the injecting of 
illegal drugs in the context of substance use disorders and by engaging with prison staff in the development of programs. 
This study has a number ofseveral limitations. As noted previously, the low overall methodological quality of the studies that met review 
inclusion criteria limits their value as evidence of the effectiveness of PNSPs for achieving health benefits. Furthermore, the challenge of 
choosing a suitable study design for assessing PNSP outcomes is complicated by logistical and ethical considerations, including those related to 














populations. SinceBecause the studies presented in this review took place in European countries, there may be publication bias. A lack of 
standardized definitions for “health outcomes” led the study team to develop its own definitions, which may have resulted in selection bias. Due 
to the diversity of study settings, findings cannot be generalized to all prisons, and variation may exist between prison subpopulations as they are 
differentiatedsubpopulationsdifferentiated by gendersex, health status, drug consumption history, and other factors. 
In conclusion, improvements in prison disease prevention ultimately will require systemic changes, including the strengthening of health systems 
as well as greater collaboration between ministries of justice, interior, and health. Winning greater support for PNSPs is not a simple undertaking, 
but it is essential for progressing toward major global targets in the fields of HIV and viral hepatitis (32, 51, 52). A less tangible but equally 
important benefit of getting PNSPs legitimized as a standard component of prison health care is that this will further affirm the health rights of 
people who inject drugs, opening the door to additional progress in reducing their marginalized status and improving their well-being. 
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Figure 1. PRISMA flow diagramPreferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram showing inclusion criteria. 
CINAHL, Cumulative Index to Nursing and Allied Health Literature. 





















































Male and female 
prisoners in O 
Pereiro de Aguiar 
(Spain) 
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 HCV prevalence decreased 
from 40% at baseline to 26% 
at follow-up. 
 HIV prevalence decreased 




































































 No new HIV or hepatitis 
infections. 
 No change in knowledge of 
hepatitis in general, 
symptoms, disease, or 
transmission. 
 Increased drug consumption, 
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 Decreased injection-related 
abscesses (Vechta).) 
 Decreased psychological 
disorders requiring treatment 
(Vechta).) 
 No overdoses occurred in 
Vechta; 1 overdose occurred 
in Lingen. 
 No new HIV or hepatitis 
infections. 
 Risk behavior decreased. 



















1994–1995  No new infections of HBV, 
HCV, or HIV. 
 No increased drug 
consumption. 
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Prisoners in one1 
male-only and 
one1 female-only 
prison in Berlin (, 
Germany) 
 Baseline: 
  57 men 
 , 117 
women  
 Follow-up: 
  43 men 





















































 Baseline: HIV, HBV, and 
HCV 
seroprevalencesseroprevalence 
rates were 18%, 53%%, and 
82%, respectively (both 
cohorts combined). 
 Follow-up: No new HBV or 
HIV infections in either 
cohort. 
 Follow-up: 1 new HCV 









































Abbreviations: AIDS, acquired immunodeficiency syndrome; HBV, hepatitis B virus,; HCV, hepatitis C virus,; HIV, human immunodeficiency 
virus; NGO, nongovernmental organization; PNSP, prison needle and syringe program. 
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